| The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel, RP Baum, D Hörsch, ... European journal of nuclear medicine and molecular imaging 40, 800-816, 2013 | 848 | 2013 |
| Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs DJ Kwekkeboom, J Mueller-Brand, G Paganelli, LB Anthony, S Pauwels, ... Journal of Nuclear Medicine 46 (1 suppl), 62S-66S, 2005 | 556 | 2005 |
| Radiopharmaceutical therapy in cancer: clinical advances and challenges G Sgouros, L Bodei, MR McDevitt, JR Nedrow Nature reviews Drug discovery 19 (9), 589-608, 2020 | 517 | 2020 |
| Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study L Bodei, M Cremonesi, CM Grana, N Fazio, S Iodice, SM Baio, ... European journal of nuclear medicine and molecular imaging 38, 2125-2135, 2011 | 469 | 2011 |
| Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors L Bodei, M Cremonesi, M Ferrari, M Pacifici, CM Grana, M Bartolomei, ... European journal of nuclear medicine and molecular imaging 35, 1847-1856, 2008 | 458 | 2008 |
| Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors L Bodei, M Kidd, G Paganelli, CM Grana, I Drozdov, M Cremonesi, ... European journal of nuclear medicine and molecular imaging 42, 5-19, 2015 | 430 | 2015 |
| Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study L Bodei, M Cremonesi, S Zoboli, C Grana, M Bartolomei, P Rocca, ... European journal of nuclear medicine and molecular imaging 30, 207-216, 2003 | 372 | 2003 |
| EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, R Baum, MF Bozkurt, J Czernin, ... European journal of nuclear medicine and molecular imaging 46, 2536-2544, 2019 | 328 | 2019 |
| 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors V Ambrosini, D Campana, L Bodei, C Nanni, P Castellucci, V Allegri, ... Journal of Nuclear Medicine 51 (5), 669-673, 2010 | 296 | 2010 |
| Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide G Paganelli, S Zoboli, M Cremonesi, L Bodei, M Ferrari, C Grana, ... European journal of nuclear medicine 28, 426-434, 2001 | 285 | 2001 |
| ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues RJ Hicks, DJ Kwekkeboom, E Krenning, L Bodei, S Grozinsky-Glasberg, ... Neuroendocrinology 105 (3), 295-309, 2017 | 281 | 2017 |
| EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds F Giammarile, L Bodei, C Chiesa, G Flux, F Forrer, F Kraeber-Bodere, ... European journal of nuclear medicine and molecular imaging 38, 1393-1406, 2011 | 278 | 2011 |
| Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours L Bodei, M Cremonesi, C Grana, P Rocca, M Bartolomei, M Chinol, ... European journal of nuclear medicine and molecular imaging 31, 1038-1046, 2004 | 277 | 2004 |
| Dosimetry in peptide radionuclide receptor therapy: a review M Cremonesi, M Ferrari, L Bodei, G Tosi, G Paganelli Journal of nuclear medicine 47 (9), 1467-1475, 2006 | 273 | 2006 |
| 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long … JR Strosberg, ME Caplin, PL Kunz, PB Ruszniewski, L Bodei, A Hendifar, ... The Lancet Oncology 22 (12), 1752-1763, 2021 | 236 | 2021 |
| Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective M Cremonesi, C Chiesa, L Strigari, M Ferrari, F Botta, F Guerriero, ... Frontiers in oncology 4, 210, 2014 | 204 | 2014 |
| A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors MJ Alvarez, PS Subramaniam, LH Tang, A Grunn, M Aburi, G Rieckhof, ... Nature genetics 50 (7), 979-989, 2018 | 188 | 2018 |
| Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: the experience of the European Institute of Oncology Group M Chinol, L Bodei, M Cremonesi, G Paganelli Seminars in nuclear medicine 32 (2), 141-147, 2002 | 177 | 2002 |
| Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray” B Brans, L Bodei, F Giammarile, O Lindén, M Luster, WJG Oyen, ... European journal of nuclear medicine and molecular imaging 34, 772-786, 2007 | 173 | 2007 |
| EANM procedure guideline for treatment of refractory metastatic bone pain L Bodei, M Lam, C Chiesa, G Flux, B Brans, A Chiti, F Giammarile European journal of nuclear medicine and molecular imaging 35, 1934-1940, 2008 | 165 | 2008 |
